Communiqués Orexo AB

Actions

ORX

SE0000736415

Produits pharmaceutiques

Temps réel estimé Cboe Europe Autres places de cotation 09:21:21 30/06/2026			Varia. 5j.	Varia. 1 janv.
24,15 ^SEK	-1,02%		+8,89%	-18,60%

09/06	Orexo AB annonce la nomination de Raheleh Nassaji au poste de Senior Vice President Business Development	CI
09/06	Orexo recrute une nouvelle directrice du développement commercial	FW

Communiqués

09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships	AQ
19/05	Orexo: Promising early-stage data	AQ
19/05	Orexo announces positive outcome from an in-vivo study of OX390	AQ
07/05	Report from Orexo AB’s annual general meeting May 7 2026	AQ
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review	AQ
28/04	Orexo : Earnings Call Q1 2026 (engelska)	PU
28/04	Orexo : Earnings Call Q1 2026	PU
28/04	Orexo : Q1 2026 Interim Report MASTER	PU
28/04	Orexo : Q1 2026 Interim Report 2026	PU
28/04	Orexo : Audiocast	PU
28/04	Orexo Q1 2026 Interim Report	AQ
21/04	Invitation to presentation of Orexo´s Q1 2026 Interim Report	AQ
31/03	Number of shares and votes in Orexo	AQ
30/03	Notice of Annual General Meeting of Orexo	AQ
27/03	Orexo : Sustainability Report 2025	PU
27/03	Orexo publishes Annual Report for 2025	AQ
24/03	Orexo: Key takeaways from R&D Day	AQ
24/03	Orexo R&D Day - Building global leadership in amorphous drug delivery	AQ
06/03	Invitation & Agenda: Orexo R&D Day on March 24	AQ
06/03	Orexo: Management changes no major surprise	AQ
06/03	Orexo changes the organizational structure and management team to increase focus on development of new products	AQ
04/03	Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028	AQ
19/02	Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs	AQ
06/02	Orexo: Busy quarter paves the way for a fresh start – Q4 review	AQ
05/02	Orexo Interim Report Q4 2025, incl. Full Year Report	AQ